期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Typing of biliary tumor thrombus influences the prognoses of patients with hepatocellular carcinoma 被引量:5
1
作者 Juxian Sun Jiayi Wu +7 位作者 Chang Liu Jie Shi Yonggang Wei Jianyin Zhou Zhibo Zhang Wan Yee Lau maolin yan Shuqun Cheng 《Cancer Biology & Medicine》 SCIE CAS CSCD 2021年第3期808-815,共8页
Objective:To establish a new classification of biliary tumor thrombus(BTT).Methods:Overall survival of patients with BTT was first used to determine whether it correlated with current hepatocellular carcinoma staging ... Objective:To establish a new classification of biliary tumor thrombus(BTT).Methods:Overall survival of patients with BTT was first used to determine whether it correlated with current hepatocellular carcinoma staging systems.Univariate and multivariate analyses were used to determine factors affecting the overall survival(OS)to form the basis of our new classification for BTT.Results:All 6 international staging systems showed overlapping survival curves.Univariate followed by multivariate analyses showed that total bilirubin and intrahepatic/extrahepatic BTT were significant risk factors of OS.Based on these data,a new BTT classification was defined as:TypeⅠ:intrahepatic BTT;and TypeⅡ:extrahepatic BTT involving a common bile duct or common hepatic duct.TypeⅠwas further subdivided into type Ia:BTT involving a second-order intrahepatic duct or above,and type Ib:BTT involving a first-order intrahepatic duct.TypeⅡwas further subdivided into typeⅡa and typeⅡb using a cut-off total bilirubin(TB)>300μmol/L.The numbers(percentages)of patients with typesⅠandⅡBTT were 69(34.2%)and 133(65.8%),respectively.The median OS of typeⅠpatients was significantly higher than that of typeⅡpatients(37.5 months vs.23.2 months;P=0.002).Using subgroup analyses,OS outcomes were significantly different between the subgroups of typeⅡb and type IIa,although there was no significant difference between the type Ia and type Ib subgroups(P=0.07).Conclusions:A new BTT classification was established to predict prognoses of HCC patients with BTT who underwent liver resection. 展开更多
关键词 Hepatocellular carcinoma biliary tumor thrombus staging system SURGERY PROGNOSIS
下载PDF
靶向和免疫治疗在肝细胞癌新辅助治疗中的应用 被引量:1
2
作者 傅仰楷 严茂林 《中华肝脏外科手术学电子杂志》 CAS 2022年第6期559-562,共4页
我国是肝细胞癌(HCC)大国,全世界约半数新发HCC患者来自中国,每年死亡病例数占全球55%以上[1,2]。HCC作为我国第4位常见的恶性肿瘤,其病死率占癌症相关死亡原因的第2位[3]。目前HCC的治疗方式包括根治性治疗(手术切除、肝移植、射频消... 我国是肝细胞癌(HCC)大国,全世界约半数新发HCC患者来自中国,每年死亡病例数占全球55%以上[1,2]。HCC作为我国第4位常见的恶性肿瘤,其病死率占癌症相关死亡原因的第2位[3]。目前HCC的治疗方式包括根治性治疗(手术切除、肝移植、射频消融、微波消融)、系统治疗(靶向治疗、免疫治疗)、支持治疗等。BCLC分期0~A期患者可选择肝切除、射频消融和肝移植;而B期和C期患者只能分别选择TACE和系统治疗。我国《原发性肝癌诊疗规范(2019年版)》将肝切除术的适应证从Ⅰa期扩展到Ⅲa期(BCLC分期A期到C期)。特别是部分具有高危复发因素的中晚期HCC纳入手术适应证后,其远期疗效不甚理想。 展开更多
关键词 肝细胞 靶向治疗 免疫治疗 新辅助治疗
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部